Gencurix Inc (229000) - Total Liabilities

Latest as of June 2026: ₩18.57 Billion KRW ≈ $12.58 Million USD

Based on the latest financial reports, Gencurix Inc (229000) has total liabilities worth ₩18.57 Billion KRW (≈ $12.58 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 229000 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Gencurix Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how Gencurix Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Gencurix Inc (229000) total assets.

Gencurix Inc Competitors by Total Liabilities

The table below lists competitors of Gencurix Inc ranked by their total liabilities.

Company Country Total Liabilities
Battalion Oil Corp
NYSE MKT:BATL
USA $511.94 Million
Genoway
PA:ALGEN
France €20.43 Million
Qinetiq Group PLC
LSE:QQ
UK GBX1.19 Billion
Promise Technology Inc
TW:3057
Taiwan NT$285.04 Million
TINYBUILD REGSCAT3 DL-001
F:8Z3
Germany €11.50 Million
ES Ceramics Technology Bhd
KLSE:0100
Malaysia RM125.72 Million
Union Corporation
KO:000910
Korea ₩212.48 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Gencurix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Gencurix Inc balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.48 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.47 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.60 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Gencurix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Gencurix Inc (2016–2025)

The table below shows the annual total liabilities of Gencurix Inc from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 ₩15.74 Billion
≈ $10.67 Million
+3.90%
2024-12-31 ₩15.15 Billion
≈ $10.27 Million
-29.54%
2023-12-31 ₩21.50 Billion
≈ $14.57 Million
-30.12%
2022-12-31 ₩30.76 Billion
≈ $20.85 Million
+26.62%
2021-12-31 ₩24.30 Billion
≈ $16.47 Million
+129.19%
2020-12-31 ₩10.60 Billion
≈ $7.18 Million
+374.88%
2019-12-31 ₩2.23 Billion
≈ $1.51 Million
+136.53%
2018-12-31 ₩943.77 Million
≈ $639.58K
-1.26%
2017-12-31 ₩955.78 Million
≈ $647.72K
-7.10%
2016-12-31 ₩1.03 Billion
≈ $697.21K
--

About Gencurix Inc

KQ:229000 Korea Diagnostics & Research
Market Cap
$31.07 Million
₩45.85 Billion KRW
Market Cap Rank
#23748 Global
#1641 in Korea
Share Price
₩1957.00
Change (1 day)
+0.88%
52-Week Range
₩1400.00 - ₩5870.00
All Time High
₩23845.65
About

Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detecti… Read more